Generate a tailored SOP for Dr. Andrew Armstrong. Improve your application with a focused, well-structured draft.
Andrew John Armstrong is a clinical translational investigator who focuses on precision therapies and biomarkers for advanced prostate and genitourinary cancers. He oversees a large research team of clinical lab-based investigators aimed at improving patient outcomes and preventing metastatic disease while enhancing the understanding of aggressive prostate cancer biology. His key research themes include identifying predictors of clinical efficacy for therapies in advanced prostate cancer, designing novel clinical trials for pharmacodynamic and translational studies in various cancers including prostate, kidney, and bladder, and developing pre-operative models for drug development and testing of novel agents. Furthermore, he is engaged in designing rational combination therapies for men with metastatic hormone-refractory prostate cancer and examining surrogate markers of mortality in the context of these conditions. His work encompasses the biologic basis of prostate cancer lineage plasticity, immune evasion, hormone therapy, and metastasis.
Duke Department of Surgery • Durham, NC
Duke Department of Surgery • Durham, NC
Duke Department of Pharmacology and Cancer Biology • Durham, NC
Duke Department of Surgery • Durham, NC
Duke Department of Medicine • Durham, NC
Department of Biomedical Engineering (MS program)